Investment Rating - The investment rating for the company is "Accumulate" (maintained) [2] Core Views - The company has successfully promoted its products through external channels and accelerated its R&D progress [7] - The company has established a differentiated product portfolio in the hypertension field, enhancing its brand influence in chronic disease management [7] - The company is expected to achieve revenue of 44.54 billion, 53.44 billion, and 62.53 billion yuan, and net profit of 6.28 billion, 6.90 billion, and 7.96 billion yuan from 2025 to 2027, with corresponding PE ratios of 89.6, 81.6, and 70.8 [7] Financial Performance - In the first half of 2025, the company achieved revenue of 2.131 billion yuan, a year-on-year increase of 4.32%, and a net profit of 365 million yuan, a year-on-year increase of 6.10% [7] - The company’s R&D investment in the first half of 2025 was 542 million yuan, accounting for 25.43% of revenue [7] - The company’s revenue projections for 2025E, 2026E, and 2027E are 44.54 billion, 53.44 billion, and 62.53 billion yuan respectively, with net profit projections of 6.28 billion, 6.90 billion, and 7.96 billion yuan [6][7] Market Performance - The company’s stock performance over the last 12 months shows a range of fluctuations, with a maximum increase of 101% compared to the benchmark index [4]

智通财经APP获悉，阿斯利康(AZN.US)近日宣布，其试验阶段的高血压药物Baxdrostat能有效降低难治 性或控制不佳的高血压患者的血压，为这款潜在"重磅炸弹"药物的发展前景注入强心针。 据阿斯利康提供的数据显示，在美国，约50%接受多种治疗的高血压患者仍无法有效控制血压。 Baxdrostat属于新型醛固酮合酶抑制剂。醛固酮被认为是引发高血压的关键激素因素。阿斯利康表示， 这款口服药物的耐受性良好，安全性表现优异。公司称，周一公布的初步数据将提交给全球各地的监管 机构。 目前，在首席执行官Pascal Soriot的领导下，阿斯利康已成为肿瘤药物领域的巨头。不过，这家英国制 药公司在其他疾病领域也拥有丰富的研发管线，心血管、肾脏及代谢疾病领域被视为未来增长的核心方 向。 消息公布后，阿斯利康在伦敦股市早盘一度上涨 2.1%。截至上周五收盘，该公司股价年初至今基本持 平。 Baxdrostat是阿斯利康2023年以最高18亿美元收购CinCor Pharma Inc.时纳入旗下的药物。阿斯利康认 为，这款药物的年销售额有望超过50亿美元，而巴克莱银行则预计，作为单药使用时其年销售额约为20 亿美元。 该 ...